弥漫大B细胞淋巴瘤患者PD-L1/PD-L2表达水平与临床病理及预后的关系  

Relationship between PD-L1/PD-L2 and clinical pathology,prognosis in patients with diffuse large B cell lymphoma

作　　者：禹环[1] 符丽梅[1] YU Huan;FU Limei(Department of Hematology,Chenzhou first people􀆳s Hospital,Chenzhou,Hunan,China,423000)

机构地区：[1]郴州市第一人民医院血液科,湖南郴州423000

出　　处：《分子诊断与治疗杂志》2020年第9期1163-1166,1170,共5页Journal of Molecular Diagnostics and Therapy

基　　金：湖南省自然科学基金(2018JJ6035)。

摘　　要：目的探讨弥漫大B细胞淋巴瘤(DLBCL)患者细胞程式死亡配体-1/细胞程式死亡配体-2(PD-L1/PD-L2)表达水平与临床病理及预后的关系。方法选取2013年1月至2017年1月在本院治疗的DLBCL患者97例为研究组,检测其PD-L1、PD-L2表达水平,分析PD-L1/PD-L2表达水平与临床病理的关系;统计患者术后3年生存情况,分析PD-L1/PD-L2表达水平与术后生存期的关系。结果PD-L1表达阳性者肿瘤部位在结内、肿瘤分期Ⅲ~Ⅳ期、病理分级ABC、存在靶器官受损的人数比例高于PD-L1表达阴性者,差异有统计学意义(P<0.05),PD-L2表达阳性者肿瘤部位在结内、肿瘤分期Ⅲ~Ⅳ期、存在靶器官受损的人数比例高于PD-L2表达阴性者,差异有统计学意义(P<0.05);经多元logistic回归分析,肿瘤部位在结内、肿瘤分期为Ⅲ~Ⅳ期、病理类型为ABC、靶器官受损是影响PD-L1、PD-L2阳性表达的危险因素(P<0.05),PD-L1阳性组3年生存率低于PD-L1阴性组,3年死亡率及3年复发率高于PD-L1阴性组(P<0.05),PD-L2阳性组3年生存率低于PD-L2阴性组,3年死亡率及3年复发率高于PD-L2阴性组(P<0.05);PD-L1阳性组中位生存时间为34.75个月,PD-L2阳性组中位生存时间为33.5个月。结论DLBCL患者PD-L1、PD-L2表达水平与肿瘤部位、肿瘤分期、病理分级、靶器官受损有关,并且PD-L1、PD-L2阳性表达者3年死亡率、复发率高于PD-L1、PD-L2阴性表达者。Objective To explore the relationship between expression of programmed death ligand-1/programmed death ligand-2(PD-L1/PD-L2)and clinical pathology,prognosis in patients with diffuse large B cell lymphoma(DLBCL). Methods A total of 97 DLBCL patients who were treated in the hospital from January 2013 to January 2017 were enrolled as the research subjects. The expression levels of PD-L1 and PD-L2 were detected. The relationship between PD-L1/PD-L2 and clinical pathology was analyzed. The survival situations of patients at 3 years after surgery were statistically analyzed. The relationship between PD-L1/PD-L2 and postoperative survival was analyzed. ResultsThe proportion of PD-L1 positive patients whose tumor site is in the nodal,tumor stageⅢ-Ⅳ,pathological grade ABC,and target organ damage is higher than that of PD-L1 negative patients,the difference is statistically significant(P<0.05). The proportion of PD-L2 positive patients whose tumor site is in the nodal,tumor stageⅢ-Ⅳ,and target organ damage is higher than that of PD-L2 negative patients(P<0.05). The multiple Logistic regression analysis showed that tumors inside nodules,tumor staging at stageⅢ-Ⅳ,pathological grading at grade ABC and target organ damage were risk factors affecting the positive expression of PD-L1(P<0.05),while tumors inside nodules,tumor staging at stageⅢ-Ⅳand target organ damage were risk factors affecting the positive expression of PD-L2(P<0.05). The 3-year survival rate in the PD-L1 positive group was lower than that in the PD-L1 negative group,while 3-year mortality rate and recurrence rate were higher than those in the PD-L1 negative group(P<0.05). The 3-year survival rate in the PD-L2 positive group was lower than that in the PD-L2 negative group,while 3-year mortality rate and recurrence rate were higher than those in the PD-L2 negative group(P<0.05). The median survival time in the PD-L1 positive group and the PD-L2 positive group was 34.75 months and 33.5 months,respectively.Conclusion The expression levels of PD-L1

关 键 词：弥漫大B细胞淋巴瘤 细胞程式死亡配体-1 细胞程式死亡配体-2 临床病理 预后 

分 类 号：R733.1[医药卫生—肿瘤]